Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome-A Pilot Study.
Tero SievänenTiina JokelaMatti HyvärinenTia-Marje KorhonenKirsi PylvänäinenJukka-Pekka MecklinJuha KarvanenElina SillanpääToni T SeppäläEija K LaakkonenPublished in: Cancer prevention research (Philadelphia, Pa.) (2024)
The development of cancer risk prediction models is key to improving the survival of patients with LS. This pilot study describes a serum miRNA signature-based risk prediction model that predicts LS cancer incidence within 4 years, although further validation is required.